P395 - EFFECTS OF CURCUMIN SUPPLEMENTATION ON INFLAMMATORY MARKERS AND CLINICAL OUTCOMES IN CRITICALLY ILL PATIENTS WITH SEPSIS: A RANDOMIZED CONTROLLED TRIAL

P395

EFFECTS OF CURCUMIN SUPPLEMENTATION ON INFLAMMATORY MARKERS AND CLINICAL OUTCOMES IN CRITICALLY ILL PATIENTS WITH SEPSIS: A RANDOMIZED CONTROLLED TRIAL

A. Mansour^1,*, S. Ghasemian Moghaddam², A. Heroabadi², S. M. Sajjadi-Jazi¹, N. Mohamadi Afrakoti², S. M. Marashi², H. Imani³

¹Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, ²Anesthesiology and Critical Care Department, Shariati Hospital, Tehran University of Medical Sciences, ³Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic Of

Rationale: This study aimed to evaluate the effects of curcumin supplementation on inflammatory markers and clinical outcomes in septic patients.

Methods: This randomized, double-blind, placebo-controlled trial was conducted at Shariati Hospital, Tehran, Iran. A total of 46 critically ill patients with sepsis were randomly assigned to receive either curcumin (1000 mg twice a day) or placebo for five days. Serum levels of inflammatory markers, including IL-6, TNF-α, ESR, and CRP, were measured at baseline (day 0) and on day 5. Clinical outcomes, such as Sequential Organ Failure Assessment (SOFA) scores and intensive care unit length of stay (ICU LOS), were also assessed. Independent t-tests and chi-square tests were used to compare baseline characteristics, while a repeated measures general linear model was applied to analyze changes over time, with an intention-to-treat analysis conducted.

Results: A total of 46 patients (mean age±standard deviation: 60.2±19.5 years) were randomized into two groups: 20 patients received curcumin and 26 received a placebo. Males comprised 63% of participants, with 55% in the curcumin group and 69% in the placebo group (p=0.322). No significant differences were observed between the two groups in terms of inflammatory markers after the intervention. Similarly, there were no significant differences in ICU LOS or SOFA scores. The ICU LOS was 10.95 days (95%CI: 7.75-14.14) in the curcumin and 13.42 days (95%CI: 9.23-17.60) in the placebo group (p=0.466). The SOFA score on Day 0 was 6.40 (95%CI: 5.25-7.55) in the curcumin and 6.74 (95%CI: 5.56-7.90) in the placebo group, while on Day 5, it was 6.75 (95%CI: 5.60-7.90) and 7.82 (95%CI: 6.32-9.33), respectively (p=0.164).

Image:

Conclusion: High-dose curcumin supplementation did not significantly improve inflammatory markers, ICU LOS, or SOFA scores in critically ill patients with sepsis.

Disclosure of Interest: None declared